Breast Cancer

BREAST CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

How the Coronavirus Pandemic May Affect Cancer Clinical Trials

Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Can Earlier Mammographic Screenings Affect Mortality Rates?

When should women begin getting mammograms? Guidance can vary based on an individual’s family history or other high-risk identifiers, but physicians advise that women get screened for breast cancer consistently by at least age 50. However, a recent study out of the United Kingdom suggests that starting breast cancer screenings earlier could have a large…
HRD Score Did Not Predict Benefit of Platinum Therapy in TNBC

The assay may play a role in determining use of other treatments like PARP inhibitors.
Prognosis for Early-Stage Breast Cancer Remains Good Despite Pandemic-Related Delays in Surgery

A retrospective review of women treated for breast cancer diagnosed in 2010-2016 demonstrated the effects of delays in time to surgery for DCIS and cT1-2N0 disease.
Effective Communication Is Key to Improving Abnormal Mammogram Follow-Up

Regardless of the type of treatment center, effective communication remained important.

VIDEO SERIES

The Phase 3 PlanB Trial

Continue to Work?

Drug Resistance to CDK4/6 Inhibitors

Comparing Ribociclib and Palbociclib

Ribociclib, Abemaciclib, and Palbociclib

The Potential of CDK4/6 Inhibitors

How Cyclin D Plays A Role

2016 SABCS: Clinical Insights Telli

2016 SABCS: Clinical Insights Oregan

HER2-positive Metastatic and TNBC

Frontline Treatments

Treatment-related Neuropathy

ER-positive, HER2-negative

Emerging Medicines

Triple-negative Breast Cancer

Insights from the Lab and Clinic

Trastuzumab Resistance

Biologic Role of HER2

Strategies in Management

BREAST CANCER NEWS

Most invasive breast cancers present as adenocarcinomas and are classified based on microscopic appearance. The most common histologic types of invasive breast cancer are ductal and lobular carcinomas, accounting for approximately 75% and 15% of all cases in the US, respectively.3

Promising Findings for Palbociclib Plus Fulvestrant in the Frontline Setting for HR-Positive, HER2-Negative MBC

September 21, 2020

The ASCO/CAP Expert Panel continues to recommend IHC as the only primary screening test for predicting benefit of endocrine therapy in breast cancer.

Addition of a CDK4/6 Inhibitor to Adjuvant Endocrine Therapy Improves Outcomes in HR+, HER2-, High-Risk Early Breast Cancer

September 20, 2020

For the first time in a decade, the American Cancer Society has updated its breast screening guideli

No Benefit for Addition of Palbociclib to Adjuvant Endocrine Therapy in Early HR-Positive, HER2-Negative Breast Cancer

September 20, 2020

An exceptional response to cetuximab in a patient with EGFR-amplified triple-negative breast cancer suggests EGFR copy number may help identify responders.

Neoadjuvant Atezolizumab Plus Chemotherapy Improves pCR in TNBC

September 20, 2020

Patients who undergo this cosmetic procedure should be counseled on the increased risk of BIA ALCL.

Recall of Specific Types of Breast Implants and Tissue Expanders Has Far-Reaching Impact on Patients With Breast Cancer

September 18, 2020

Next post in Breast Cancer

FDA: Efficacy, Safety Concerns With Breast Cancer Combo Therapy